Holen Sie sich die Stockscreener-App
1.76
12.82%
0.20
Handel nachbörslich:
1.76
Humacyte Inc Aktie (HUMA) Neueste Nachrichten
Live market analysis of Humacyte Inc. Equity Warrant2025 Risk Factors & AI Powered Market Entry Strategies - newser.com
Understanding Humacyte Inc. Equity Warrant’s price movementJuly 2025 Volume & Fast Gain Swing Trade Alerts - newser.com
Should I hold or sell Humacyte Inc. Equity Warrant stock in 20252025 Top Decliners & AI Driven Stock Reports - newser.com
Is Humacyte Inc. Equity Warrant forming a bottoming baseGap Down & Fast Moving Stock Watchlists - newser.com
Applying sector rotation models to Humacyte Inc. Equity Warrant2025 Price Action Summary & Smart Investment Allocation Tips - newser.com
Is Humacyte Inc. stock trading near support levelsBreakout Watch & Low Risk High Win Rate Picks - newser.com
Applying chart zones and confluence areas to Humacyte Inc.July 2025 Movers & High Yield Equity Trading Tips - newser.com
Using fundamentals and technicals on Humacyte Inc. Equity WarrantEarnings Recap Summary & Risk Managed Investment Entry Signals - newser.com
Relative strength of Humacyte Inc. in sector analysisMarket Movers & Long-Term Growth Plans - newser.com
Will Humacyte Inc. stock gain from government policiesJobs Report & Verified Short-Term Plans - newser.com
Can a trend reversal in Humacyte Inc. Equity Warrant lead to recoveryTrade Entry Summary & Entry Point Strategy Guides - newser.com
Humacyte (HUMA) Is Down 25.7% After Reporting Strong Symvess Trauma Results and Completing $60M Equity Raise - Yahoo Finance
Humacyte shares sink as it announces pricing of $60M direct offering - MSN
Advanced analytics toolkit walkthrough for Humacyte Inc.Take Profit & Long-Term Capital Growth Strategies - newser.com
Top chart patterns to watch in Humacyte Inc.Earnings Overview Summary & AI Powered Market Entry Ideas - newser.com
Building trade automation scripts for Humacyte Inc.July 2025 PreEarnings & Fast Gaining Stock Reports - newser.com
Real time social sentiment graph for Humacyte Inc.Weekly Stock Analysis & Capital Efficiency Focused Ideas - newser.com
Published on: 2025-10-10 04:58:04 - newser.com
Is Humacyte Inc. stock poised for growthWeekly Trade Report & Safe Capital Growth Plans - newser.com
Humacyte Announces $60M Stock and Warrants Offering - MSN
Published on: 2025-10-09 06:28:01 - newser.com
Is Humacyte Inc. Equity Warrant stock positioned for digital transformation2025 Retail Activity & Real-Time Volume Triggers - newser.com
Weiss Ratings Reiterates Sell (E+) Rating for Humacyte (NASDAQ:HUMA) - MarketBeat
Humacyte, Inc.Common Stock (NQ: - FinancialContent
Combat Trauma Study Results Might Change The Case For Investing In Humacyte (HUMA) - simplywall.st
What analysts say about Humacyte Inc stockRisk Mitigation Techniques & Fast Growing Investment Plans - earlytimes.in
Humacyte, Inc. (HUMA) Declines More Than Market: Some Information for Investors - Yahoo Finance
Investors Buy High Volume of Call Options on Humacyte (NASDAQ:HUMA) - MarketBeat
Humacyte: Shares Tank On Fundraising NewsWhat You Need To Know (NASDAQ:HUMA) - Seeking Alpha
Humacyte Gains 43%, Insider Trades Reap Benefit - Yahoo
Humacyte (HUMA) Valuation in Focus After Encouraging Ukraine Trauma Results and New Patent Milestone - simplywall.st
Humacyte shares plunge after announcing $60 million registered direct offering - MSN
Humacyte Prices $60 Million Oversubscribed Registered Direct Offering; Shares Tumble - MarketScreener
Humacyte prices 28.4M shares at $2.11 in registered direct offering - TipRanks
Humacyte secures $60 million in registered direct offering - Investing.com
Humacyte stock tumbles after $60 million registered direct offering - Investing.com
Humacyte announces pricing of $60.0 million oversubscribed registered direct offering - MarketScreener
Humacyte Announces Pricing of $60.0 Million Oversubscribed Registered Direct Offering - MarketScreener
Is Humacyte Inc a good long term investmentMean Reversion Trades & Breakthrough Stock Performance - earlytimes.in
Humacyte rises after positive data from humanitarian study of Symvess - MSN
HUMA: D. Boral Capital Maintains 'Buy' Rating with $25 Price Tar - GuruFocus
Humacyte's (HUMA) "Buy" Rating Reiterated at D. Boral Capital - MarketBeat
Humacyte reports positive long-term results for vascular trauma device - Investing.com India
Humacyte Announces Publication of Long-Term Results for Ukrainian Patients Treated in Real-World Combat Setting with Symvess™ - The Manila Times
Humacyte, Inc. Reports Zero Infections and High Patency Rates for Symvess in Military Medicine Journal Publication on Wartime Vascular Trauma Treatment - Quiver Quantitative
87.1% patency in 17 patients — Humacyte's Symvess shows zero infections, amputations or deaths - Stock Titan
How to monitor Humacyte Inc. with trend dashboardsEarnings Recap Summary & AI Enhanced Trading Alerts - newser.com
Why Humacyte Inc. stock remains undervaluedTrade Volume Summary & High Conviction Buy Zone Alerts - newser.com
How to integrate Humacyte Inc. Equity Warrant into portfolio analysis toolsPortfolio Update Summary & Safe Capital Investment Plans - newser.com
Developing predictive dashboards with Humacyte Inc. dataJuly 2025 Update & High Yield Stock Recommendations - newser.com
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):